Maze Therapeutics (MAZE) Cash from Investing Activities (2024 - 2026)
Maze Therapeutics (MAZE) reported Cash from Investing Activities of $6.3 million for Q1 2026, up 2198.66% on a YoY basis from $272984.9 in Q1 2025, and up 106.07% sequentially from -$103.4 million in Q4 2025.
Maze Therapeutics (MAZE) Cash from Investing Activities (2024 - 2026) Analysis & Trends
Maze Therapeutics (MAZE) has 3 years of Cash from Investing Activities data on file, last reported at $6.3 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 2198.66% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at -$164.4 million (down 13986.38% YoY), and the FY2025 full-year result was -$171.0 million, down 14805.14% from the prior year.
- Cash from Investing Activities improved to $6.3 million in Q1 2026, from -$103.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $6.3 million in Q1 2026 to a low of -$103.4 million in Q4 2025.
- A 3-year average of -$18.4 million and a median of -$299000.0 in 2025 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities sank 64834.95% in 2025 and surged 2198.66% in 2026, its largest moves.
- Tracing MAZE's Cash from Investing Activities over 3 years: stood at -$605000.0 in 2024, then slumped by 16988.76% to -$103.4 million in 2025, then soared by 106.07% to $6.3 million in 2026.
- Business Quant data shows MAZE's Cash from Investing Activities at $6.3 million in Q1 2026, -$103.4 million in Q4 2025, and -$66.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 172.62 Mn |
| 10 | Maze Therapeutics | 1.49 Bn | 1.49 Bn | 18.21 Mn | 6.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.28 Mn |
| Mar 31, 2026 | 6.28 Mn |
| Dec 31, 2025 | -103.39 Mn |
| Dec 31, 2025 | -103.39 Mn |
| Sep 30, 2025 | -66.88 Mn |
| Sep 30, 2025 | -66.88 Mn |
| Jun 30, 2025 | -393,000.00 |
| Jun 30, 2025 | -393,000.00 |
| Mar 31, 2025 | -299,000.00 |
| Mar 31, 2025 | -299,000.00 |
| Dec 31, 2024 | -605,000.00 |
| Dec 31, 2024 | -605,000.00 |
| Sep 30, 2024 | -103,000.00 |
| Sep 30, 2024 | -103,000.00 |
| Jun 30, 2024 | -160,000.00 |
| Jun 30, 2024 | -160,000.00 |
| Mar 31, 2024 | -279,000.00 |
| Mar 31, 2024 | -279,000.00 |